RECOVERY & TISSUE REPAIR / COMPARE
Wolverine, BPC-157, and TB-500 — Side by Side
Where the blend and its components share ground, where they diverge, and — most importantly — how far the evidence behind each one actually reaches.
The short version
This page lines up the Wolverine blend, BPC-157, and TB-500 on the dimensions that matter most when reading research peptides: what kind of molecule each one is, what it has been studied for, how strong that evidence is, its regulatory standing, WADA status, and its most important caution. The headline: all three are studied for recovery and tissue repair, but they occupy very different positions on the evidence ladder. BPC-157 has the deepest individual animal record plus three tiny human pilots. TB-500 carries the identity problem of a fragment whose evidence largely belongs to a larger parent protein. The Wolverine blend has the weakest evidential footing of all three — no controlled study of the combination exists — but the strongest conceptual appeal because the two mechanisms are genuinely complementary. None is an approved medicine. None is presented here with a human dose.
The comparison matrix
| Dimension | Wolverine blend | BPC-157 | TB-500 |
|---|---|---|---|
| What it is | BPC-157 + TB-500 co-formulated; no single CAS or molecular weight | Stable 15-aa gastric pentadecapeptide | Synthetic 7-aa Ac-LKKTETQ fragment of thymosin beta-4 |
| Primary mechanism | Theoretical: BPC-157 angiogenesis (VEGFR2-Akt-eNOS) + TB-500 actin regulation (G-actin sequestration) | Angiogenesis via VEGFR2 internalization and Akt-eNOS pathway [4] | Actin sequestration, cell migration, anti-scarring (Tβ4 mechanism) [6][5] |
| Most studied in | Not studied as a combination | Tendon, gut, muscle, vascular injury (rats) | Cell migration, wound/cardiac/CNS models (full-length Tβ4; rat, mouse) |
| Evidence base | Zero controlled combination studies [1][2] | 35 preclinical + 3 tiny human pilots [2][3] | Zero controlled trials of the fragment; full-length Tβ4 has a Phase 1 IV human safety study [12][1] |
| FDA status | Not approved; no approved indication | Not approved; 503A bulk-compounding ineligible (2023) | Not approved; no approved indication |
| WADA status | Both components banned; blend is banned in sport [1] | S0 prohibited at all times | Prohibited (peptide/growth-factor categories) [1] |
| Key caution | No combination evidence; theoretical synergy only [1][2] | Single-lab preclinical record; 3 tiny human pilots [3] | Fragment ≠ full protein; most efficacy data not for this molecule [1][5] |
Mechanism: how the two halves approach repair
The scientific rationale for pairing BPC-157 and TB-500 in the Wolverine blend rests on the claim that they act through complementary, largely non-overlapping pathways.
BPC-157 works primarily through angiogenesis — the growth of new blood vessels into injured tissue. Its best-characterized route is up-regulation and internalization of VEGFR2 with downstream Akt-eNOS activation; blocking that internalization blocks the angiogenic effect [4]. New vessels bring the oxygen and nutrients repair requires, and the effect is documented in tendon, gut, muscle, and vascular injury models.
TB-500 (and its parent protein thymosin beta-4) works through actin regulation — forming a 1:1 complex with monomeric G-actin, sequestering it, and thereby controlling the cytoskeletal dynamics that drive cell migration toward a wound [6]. Downstream effects attributed to thymosin beta-4 include anti-inflammatory signaling, reduced scar formation, and angiogenesis through a different set of cellular signals than BPC-157 [5].
The "synergy" argument says: BPC-157 builds the blood supply while TB-500 marshals the cells that fill the repair scaffold. That is a rational and appealing idea. It is also an unconfirmed hypothesis — no controlled study has tested whether the combination produces better outcomes than either peptide alone, or defined what the combined safety profile looks like [1][2].
Evidence base and human data
This is where the three entries genuinely separate.
The Wolverine blend has no controlled animal or human combination evidence — zero. The 2025 systematic review of BPC-157 in orthopaedic sports medicine (36 studies, 35 preclinical, 1 human) explicitly made no mention of TB-500 or any BPC-157/TB-500 combination [2]. Any claim about the blend's effects is extrapolated from data on the individual components.
BPC-157 has a decades-long animal record and three small human pilot studies, rated at evidence level IV–V (lowest tiers) [2]. A 2025 first-in-human intravenous safety pilot in two adults found no adverse events and no changes in safety biomarkers [8]. That is a safety signal in two people, not efficacy evidence. A 2025 narrative review rates the current evidence as insufficient to support clinical use and calls for rigorous trials [3].
TB-500 occupies an unusual position. The safety and pharmacokinetic human data that are sometimes cited for it actually come from a Phase 1 IV study of full-length thymosin beta-4 (40 healthy volunteers, doses to 1,260 mg, well tolerated) [12] — a different molecule. No completed controlled human trial of the TB-500 heptapeptide fragment exists for any indication [1]. Animal work with full-length Tβ4 found non-monotonic dose effects in a rat stroke model (2 and 12 mg/kg helped; 18 mg/kg did not) [11].
Regulatory and WADA status
None of the three is an approved medicine. BPC-157 was placed by the FDA in 2023 into a category of bulk drug substances not eligible for pharmacy compounding under 503A, pending further evaluation. TB-500 / thymosin beta-4 has no approved therapeutic indication and no 503A listing that would suggest compounding eligibility.
Both BPC-157 and TB-500 are prohibited in sport by the World Anti-Doping Agency — BPC-157 under the S0 non-approved-substances category, TB-500 under peptide and growth-factor categories. The Wolverine blend, containing both prohibited components, is therefore banned in and out of competition for tested athletes. Anti-doping laboratories have developed detection methods for TB-500 and its breakdown products [1].
Both peptides are distributed through non-regulated research channels. Product identity, purity, and dose are unverified outside formal studies.
Key caution for each
Each entry on this desk carries a defining caveat:
- Wolverine blend: no controlled study of the combination exists; the "synergy" claim is a theoretical extrapolation from each component's independently characterized mechanism, and combined safety is completely unknown [1][2].
- BPC-157: a broad, internally consistent preclinical signal that originated largely from one research group, with only three tiny human pilots; independent replication is limited, and the real-world safety and efficacy profile in humans remains genuinely unknown [3].
- TB-500: the marketed fragment (Ac-LKKTETQ) is not the molecule behind most efficacy data; applying full-length thymosin beta-4 results to the 7-mer is an unconfirmed extrapolation that significantly overstates what is known about TB-500 itself [1][5].
Reading them together, the lesson is consistent: coherent mechanisms, promising preclinical signals, uneven and early evidence in humans, and an important gap between what is studied and what is sold.